Overview

A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration

Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The objective of the CABERNET Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration (AMD). The Epi-Rad90™ Ophthalmic System treats neovascularization of retinal tissue by means of a focal, directional delivery of radiation to the target tissues in the retina. Using standard vitreoretinal surgical techniques, the sealed radiation source is placed temporarily over the retinal lesion by means of a handheld medical device.
Phase:
Phase 3
Details
Lead Sponsor:
NeoVista
Treatments:
Ranibizumab